| scholarly article | Q13442814 |
| P50 | author | Douglas A. Lauffenburger | Q59755238 |
| P2093 | author name string | Boyang Zhao | |
| Michael T Hemann | |||
| P2860 | cites work | Optimal control analysis in the chemotherapy of IgG multiple myeloma | Q44502348 |
| A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity | Q44924307 | ||
| Tumor size, sensitivity to therapy, and design of treatment schedules | Q45287063 | ||
| The molecular diversity of adaptive convergence. | Q46185374 | ||
| Cancer initiation with epistatic interactions between driver and passenger mutations | Q47766886 | ||
| Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. | Q51890946 | ||
| Systems biology and combination therapy in the quest for clinical efficacy. | Q51934858 | ||
| An error catastrophe in cancer? | Q52000115 | ||
| Unifying evolutionary dynamics. | Q52412964 | ||
| The genetic origin of drug resistance in neoplasms: implications for systemic therapy. | Q52688528 | ||
| Evolutionary advantage of small populations on complex fitness landscapes. | Q53417040 | ||
| Multiple-mutation theory of carcinogenesis. | Q53615521 | ||
| Average relative dose intensity and the impact on design of clinical trials. | Q54410194 | ||
| Rationale for the use of alternating non-cross-resistant chemotherapy. | Q54520436 | ||
| Origin of the resistance of leukaemic cells to folic acid antagonists. | Q54747803 | ||
| Quantitative analyses of empirical fitness landscapes | Q56532439 | ||
| Population genetics of tumor suppressor genes | Q57065420 | ||
| Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice | Q73021418 | ||
| Analysis of a local fitness landscape with a model of the rough Mt. Fuji-type landscape: application to prolyl endopeptidase and thermolysin | Q73756242 | ||
| Evolutionary dynamics of cancer in response to targeted combination therapy | Q21128788 | ||
| Genetic progression and the waiting time to cancer | Q21563505 | ||
| Molecular Evolution Over the Mutational Landscape | Q22064602 | ||
| Fitness and its role in evolutionary genetics | Q22122004 | ||
| The genetic theory of adaptation: a brief history | Q22122021 | ||
| Mutations of Bacteria from Virus Sensitivity to Virus Resistance | Q24533278 | ||
| A new theory on cancer-inducing mechanism | Q24564810 | ||
| The age distribution of cancer and a multi-stage theory of carcinogenesis | Q24564904 | ||
| Passenger deletions generate therapeutic vulnerabilities in cancer | Q24598469 | ||
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| Mutation and cancer: statistical study of retinoblastoma | Q24618185 | ||
| Distant metastasis occurs late during the genetic evolution of pancreatic cancer | Q24624284 | ||
| Cancer evolution: mathematical models and computational inference | Q27002537 | ||
| Clonal evolution in hematological malignancies and therapeutic implications | Q27027655 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Dynamics of cancer progression | Q28247846 | ||
| The clonal evolution of tumor cell populations | Q28271546 | ||
| Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance | Q28282963 | ||
| Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia | Q28478165 | ||
| Targeting the adaptability of heterogeneous aneuploids | Q28649939 | ||
| Clonal evolution in cancer | Q29547696 | ||
| Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing | Q29614647 | ||
| Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Q29615030 | ||
| The causes and consequences of genetic heterogeneity in cancer evolution | Q29615848 | ||
| Darwinian evolution can follow only very few mutational paths to fitter proteins | Q29616042 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| The patterns and dynamics of genomic instability in metastatic pancreatic cancer | Q29618121 | ||
| Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. | Q33178852 | ||
| Heterogeneous adaptive trajectories of small populations on complex fitness landscapes | Q33322521 | ||
| The impact of population size on the evolution of asexual microbes on smooth versus rugged fitness landscapes | Q33504886 | ||
| Tumor heterogeneity: causes and consequences | Q33624298 | ||
| Evolution of acquired resistance to anti-cancer therapy | Q33758382 | ||
| Progress of a half century in the study of the Luria-Delbrück distribution | Q33806584 | ||
| Evolutionary dynamics of intratumor heterogeneity. | Q33867413 | ||
| The role of replicates for error mitigation in next-generation sequencing | Q33921022 | ||
| Intratumor heterogeneity alters most effective drugs in designed combinations | Q33972115 | ||
| Tracing the tumor lineage | Q33998432 | ||
| Saturation editing of genomic regions by multiplex homology-directed repair | Q34143368 | ||
| Role of symmetric and asymmetric division of stem cells in developing drug resistance. | Q34165690 | ||
| Natural Selection and the Concept of a Protein Space | Q34233063 | ||
| Accumulation of driver and passenger mutations during tumor progression | Q34276850 | ||
| Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL) | Q34280885 | ||
| Combinatorial drug therapy for cancer in the post-genomic era. | Q34287101 | ||
| Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity | Q34287934 | ||
| Detection of ultra-rare mutations by next-generation sequencing | Q34291814 | ||
| Evolutionary dynamics of biological games | Q34295025 | ||
| Pervasive genetic hitchhiking and clonal interference in forty evolving yeast populations | Q34358875 | ||
| Tug-of-war between driver and passenger mutations in cancer and other adaptive processes | Q34409055 | ||
| Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers | Q34525966 | ||
| Tests of parallel molecular evolution in a long-term experiment with Escherichia coli | Q34694847 | ||
| A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate | Q34702164 | ||
| Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing | Q34812680 | ||
| Adaptive therapy. | Q34984307 | ||
| Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia | Q34997508 | ||
| The value of monitoring to control evolving populations | Q35038019 | ||
| Intratumor heterogeneity in evolutionary models of tumor progression | Q35065519 | ||
| The evolutionary history of lethal metastatic prostate cancer | Q35548366 | ||
| Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. | Q35596310 | ||
| Perspectives on protein evolution from simple exact models. | Q35766518 | ||
| Polyploidy can drive rapid adaptation in yeast | Q35835073 | ||
| Prediction of resistance development against drug combinations by collateral responses to component drugs | Q35854877 | ||
| A Big Bang model of human colorectal tumor growth | Q36074227 | ||
| A two-stage theory of carcinogenesis in relation to the age distribution of human cancer | Q36132593 | ||
| Clonal interference in large populations | Q36156834 | ||
| A branching process model of ovarian cancer | Q36339013 | ||
| Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort | Q36364933 | ||
| Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling | Q36406541 | ||
| Predictability of evolution depends nonmonotonically on population size | Q36535179 | ||
| Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems | Q36543455 | ||
| Strategies for optimizing combinations of molecularly targeted anticancer agents | Q36554418 | ||
| Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation | Q36598210 | ||
| Impact of deleterious passenger mutations on cancer progression | Q36637272 | ||
| Stepwise acquisition of pyrimethamine resistance in the malaria parasite | Q37274346 | ||
| Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution | Q37495481 | ||
| Evolutionary theory of cancer | Q37536213 | ||
| Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules | Q37581947 | ||
| Addressing genetic tumor heterogeneity through computationally predictive combination therapy | Q37683771 | ||
| Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine | Q37689928 | ||
| Systems approaches and algorithms for discovery of combinatorial therapies | Q37787998 | ||
| Role of optimal control theory in cancer chemotherapy | Q37846208 | ||
| Empirical fitness landscapes and the predictability of evolution | Q38218962 | ||
| Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. | Q38305991 | ||
| Collateral sensitivity of antibiotic-resistant microbes. | Q38394500 | ||
| The mathematics of cancer: integrating quantitative models | Q38644551 | ||
| Growth Curve of an Experimental Solid Tumor Following Radiotherapy | Q40074202 | ||
| Dynamics of chronic myeloid leukaemia. | Q40403398 | ||
| Quantitative evolutionary dynamics using high-resolution lineage tracking | Q40499709 | ||
| The effect of one additional driver mutation on tumor progression. | Q41846748 | ||
| Dynamics of targeted cancer therapy | Q42197906 | ||
| Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. | Q42246515 | ||
| Stochastic tunnels in evolutionary dynamics | Q42426795 | ||
| Evolutionary dynamics of tumor progression with random fitness values | Q42451818 | ||
| The NK model of rugged fitness landscapes and its application to maturation of the immune response | Q42643980 | ||
| Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. | Q42738785 | ||
| Modelling the evolution of genetic instability during tumour progression | Q43212807 | ||
| Stochastic dynamics of cancer initiation | Q43235502 | ||
| EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA | Q44068246 | ||
| Genetic variegation of clonal architecture and propagating cells in leukaemia | Q44426152 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 144-158 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Trends in cancer | Q27726777 |
| P1476 | title | Modeling Tumor Clonal Evolution for Drug Combinations Design | |
| P478 | volume | 2 |
| Q93098986 | A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors |
| Q39169154 | A population genetics perspective on the determinants of intra-tumor heterogeneity |
| Q92541944 | Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction |
| Q64066380 | Calling Variants in the Clinic: Informed Variant Calling Decisions Based on Biological, Clinical, and Laboratory Variables |
| Q37397222 | Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations |
| Q92130484 | Exploiting evolutionary steering to induce collateral drug sensitivity in cancer |
| Q58802587 | Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance |
| Q50042351 | Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. |
| Q92732159 | Gpn3 Is Essential for Cell Proliferation of Breast Cancer Cells Independent of Their Malignancy Degree |
| Q89106697 | Harnessing Tumor Evolution to Circumvent Resistance |
| Q94046968 | MicroRNAs as Key Regulators of Ovarian Cancers |
| Q57465829 | On the deformability of an empirical fitness landscape by microbial evolution |
| Q89622496 | The Promising Connection Between Data Science and Evolutionary Theory in Oncology |
| Q89467746 | The role of CD133 in cancer: a concise review |
| Q88548676 | Treatment resistance in urothelial carcinoma: an evolutionary perspective |
| Q53706276 | Variable Cell Line Pharmacokinetics Contribute to Non-Linear Treatment Response in Heterogeneous Cell Populations. |
Search more.